Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1982 1
1984 1
1985 1
1986 2
1987 5
1988 2
1989 3
1990 5
1991 2
1992 5
1993 1
1994 5
1995 7
1996 4
1997 6
1998 6
1999 8
2000 6
2001 12
2002 9
2003 10
2004 10
2005 6
2006 3
2007 4
2008 4
2009 11
2010 5
2011 2
2012 5
2013 8
2014 6
2015 10
2016 3
2017 10
2018 6
2019 5
2020 4
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

201 results
Results by year
Filters applied: . Clear all
Page 1
Targeting FcRn to Generate Antibody-Based Therapeutics.
Ward ES, Ober RJ. Ward ES, et al. Trends Pharmacol Sci. 2018 Oct;39(10):892-904. doi: 10.1016/j.tips.2018.07.007. Epub 2018 Aug 22. Trends Pharmacol Sci. 2018. PMID: 30143244 Free PMC article. Review.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Howard JF Jr, et al. Among authors: ward es. Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22. Neurology. 2019. PMID: 31118245 Free PMC article. Clinical Trial.
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Newland AC, Sánchez-González B, Rejtő L, Egyed M, Romanyuk N, Godar M, Verschueren K, Gandini D, Ulrichts P, Beauchamp J, Dreier T, Ward ES, Michel M, Liebman HA, de Haard H, Leupin N, Kuter DJ. Newland AC, et al. Among authors: ward es. Am J Hematol. 2020 Feb;95(2):178-187. doi: 10.1002/ajh.25680. Epub 2019 Dec 10. Am J Hematol. 2020. PMID: 31821591 Free PMC article. Clinical Trial.
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.
Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N. Ulrichts P, et al. Among authors: ward es. J Clin Invest. 2018 Oct 1;128(10):4372-4386. doi: 10.1172/JCI97911. Epub 2018 Jul 24. J Clin Invest. 2018. PMID: 30040076 Free PMC article. Clinical Trial.
In memoriam: Jefferson Foote.
Ward ES, Jones P, Buss T, Rada C, Winter G, Willson R. Ward ES, et al. MAbs. 2021 Jan-Dec;13(1):1870059. doi: 10.1080/19420862.2020.1870059. MAbs. 2021. PMID: 33435811 Free PMC article.
Targeting FcRn for the modulation of antibody dynamics.
Ward ES, Devanaboyina SC, Ober RJ. Ward ES, et al. Mol Immunol. 2015 Oct;67(2 Pt A):131-41. doi: 10.1016/j.molimm.2015.02.007. Epub 2015 Mar 9. Mol Immunol. 2015. PMID: 25766596 Free PMC article. Review.
201 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page